Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP decreased its holdings in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) by 3.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 716,134 shares of the company’s stock after selling 29,200 shares during the quarter. Two Sigma Advisers LP owned approximately 0.75% of Assertio worth $624,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ASRT. Stifel Financial Corp acquired a new stake in Assertio during the fourth quarter worth about $27,000. Commonwealth Equity Services LLC acquired a new stake in Assertio during the fourth quarter worth about $30,000. Wealthfront Advisers LLC bought a new position in Assertio in the 4th quarter worth about $53,000. Marshall Wace LLP bought a new position in Assertio in the 4th quarter worth about $64,000. Finally, Palumbo Wealth Management LLC grew its position in Assertio by 10.6% in the 4th quarter. Palumbo Wealth Management LLC now owns 205,598 shares of the company’s stock worth $179,000 after purchasing an additional 19,637 shares during the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.

Assertio Trading Up 2.0%

Assertio stock opened at $0.67 on Wednesday. The firm has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.77. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57. The stock has a market capitalization of $64.17 million, a PE ratio of -0.92, a price-to-earnings-growth ratio of 3.25 and a beta of 0.32. Assertio Holdings, Inc. has a 12-month low of $0.51 and a 12-month high of $1.80.

Assertio (NASDAQ:ASRT) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.08). The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $27.52 million. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. During the same quarter last year, the business earned $0.04 earnings per share. As a group, equities research analysts expect that Assertio Holdings, Inc. will post -0.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ASRT has been the subject of several recent analyst reports. Alliance Global Partners restated a “buy” rating on shares of Assertio in a research report on Tuesday, May 13th. HC Wainwright restated a “buy” rating and issued a $3.50 target price on shares of Assertio in a research report on Monday, May 19th. Wall Street Zen cut shares of Assertio from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, Industrial Alliance Securities set a $1.75 target price on shares of Assertio in a research report on Friday, March 14th.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.